Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life.

Rowen D, Brazier J, Mukuria C, Keetharuth A, Risa Hole A, Tsuchiya A, Whyte S, Shackley P.

Med Decis Making. 2016 Feb;36(2):210-22. doi: 10.1177/0272989X15619389. Epub 2015 Dec 15.

PMID:
26670663
2.

A qualitative study to explore the attitude of clinical staff to the challenges of caring for obese patients.

Lumley E, Homer CV, Palfreyman S, Shackley P, Tod AM.

J Clin Nurs. 2015 Dec;24(23-24):3594-604. doi: 10.1111/jocn.13016. Epub 2015 Oct 14.

PMID:
26467348
3.

The random card sort method and respondent certainty in contingent valuation: an exploratory investigation of range bias.

Shackley P, Dixon S.

Health Econ. 2014 Oct;23(10):1213-23. doi: 10.1002/hec.2980. Epub 2013 Aug 6.

PMID:
23922327
4.

Cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A: results from the botulinum toxin for the upper limb after stroke (BoTULS) trial.

Shackley P, Shaw L, Price C, van Wijck F, Barnes M, Graham L, Ford GA, Steen N, Rodgers H.

Toxins (Basel). 2012 Dec;4(12):1415-26.

5.

Putting a value on the avoidance of false positive results when screening for inherited metabolic disease in the newborn.

Dixon S, Shackley P, Bonham J, Ibbotson R.

J Inherit Metab Dis. 2012 Jan;35(1):169-76. doi: 10.1007/s10545-011-9354-0. Epub 2011 May 27.

PMID:
21617925
6.

Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial: effect on impairment, activity limitation, and pain.

Shaw LC, Price CI, van Wijck FM, Shackley P, Steen N, Barnes MP, Ford GA, Graham LA, Rodgers H; BoTULS Investigators.

Stroke. 2011 May;42(5):1371-9. doi: 10.1161/STROKEAHA.110.582197. Epub 2011 Mar 17.

7.

The social value of a QALY: raising the bar or barring the raise?

Donaldson C, Baker R, Mason H, Jones-Lee M, Lancsar E, Wildman J, Bateman I, Loomes G, Robinson A, Sugden R, Prades JL, Ryan M, Shackley P, Smith R.

BMC Health Serv Res. 2011 Jan 11;11:8. doi: 10.1186/1472-6963-11-8.

8.

Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project.

Baker R, Bateman I, Donaldson C, Jones-Lee M, Lancsar E, Loomes G, Mason H, Odejar M, Pinto Prades JL, Robinson A, Ryan M, Shackley P, Smith R, Sugden R, Wildman J; SVQ Research Team.

Health Technol Assess. 2010 May;14(27):1-162. doi: 10.3310/hta14270.

9.

BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.

Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, Barnes M, Ford G, Graham L; BoTULS investigators.

Health Technol Assess. 2010 May;14(26):1-113, iii-iv. doi: 10.3310/hta14260.

10.

Assessing current health-related quality of life questionnaires administered to patients with venous ulcers: can they be used in economic evaluations?

Palfreyman SJ, Shackley P, Brazier JE.

J Clin Nurs. 2010 Mar;19(5-6):892-7. doi: 10.1111/j.1365-2702.2009.03172.x. Review. No abstract available.

PMID:
20500332
11.

A prospective randomised controlled trial and economic modelling of antimicrobial silver dressings versus non-adherent control dressings for venous leg ulcers: the VULCAN trial.

Michaels JA, Campbell WB, King BM, Macintyre J, Palfreyman SJ, Shackley P, Stevenson MD.

Health Technol Assess. 2009 Nov;13(56):1-114, iii. doi: 10.3310/hta13560.

12.

Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial).

Michaels JA, Campbell B, King B, Palfreyman SJ, Shackley P, Stevenson M.

Br J Surg. 2009 Oct;96(10):1147-56. doi: 10.1002/bjs.6786.

PMID:
19787753
13.

Evaluation of the cost-effectiveness of root canal treatment using conventional approaches versus replacement with an implant.

Pennington MW, Vernazza CR, Shackley P, Armstrong NT, Whitworth JM, Steele JG.

Int Endod J. 2009 Oct;42(10):874-83. doi: 10.1111/j.1365-2591.2009.01582.x.

PMID:
19751289
14.

Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.

Rodgers H, Shaw L, Price C, van Wijck F, Barnes M, Graham L, Ford G, Shackley P, Steen N; BoTULS Investigators.

Trials. 2008 Oct 23;9:59. doi: 10.1186/1745-6215-9-59.

15.

A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial.

Marson AG, Appleton R, Baker GA, Chadwick DW, Doughty J, Eaton B, Gamble C, Jacoby A, Shackley P, Smith DF, Tudur-Smith C, Vanoli A, Williamson PR.

Health Technol Assess. 2007 Oct;11(37):iii-iv, ix-x, 1-134.

16.

A comparison of the 'cost per child treated' at a primary care-based sedation referral service, compared to a general anaesthetic in hospital.

Jameson K, Averley PA, Shackley P, Steele J.

Br Dent J. 2007 Sep 22;203(6):E13. Epub 2007 Jul 13.

PMID:
17632457
17.

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.

Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR; SANAD Study group.

Lancet. 2007 Mar 24;369(9566):1016-26.

18.

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.

Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR; SANAD Study group.

Lancet. 2007 Mar 24;369(9566):1000-15.

19.

Preferences for access to the GP: a discrete choice experiment.

Rubin G, Bate A, George A, Shackley P, Hall N.

Br J Gen Pract. 2006 Oct;56(531):743-8.

20.

Implicit versus explicit ranking: on inferring ordinal preferences for health care programmes based on differences in willingness-to-pay.

Olsen JA, Donaldson C, Shackley P; EuroWill Group.

J Health Econ. 2005 Sep;24(5):990-6.

PMID:
15893827
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk